We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips
Read MoreHide Full Article
Key Takeaways
Illumina reported Q4 adjusted EPS of $1.35, up 42.1% year over year, topping estimates.
ILMN shares fell 10.4% after results as gross margin slipped 45 bps on higher costs.
Illumina expects 2026 revenues of $4.50-$4.60B and non-GAAP EPS of $5.05-$5.20.
Illumina Inc. (ILMN - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.35, which topped the Zacks Consensus Estimate by 7.4%. The figure was up 42.1% on a year-over-year basis.
Including one-time items, the company’s GAAP EPS was $2.16 compared with 73 cents a year ago.
Full-year adjusted EPS was $4.84, up 16.3% year over year.
Illumina’s Revenues
Fourth-quarter revenues amounted to $1.16 billion, up 5.4% year over year and up 4% on a constant-currency basis. The top line marginally beat the Zacks Consensus Estimate by 0.3%.
Full-year revenues amounted to $4.34 billion, up 0.2% year over year and flat on a constant-currency basis.
Following the earnings announcement, Illumina shares declined 10.4% last Friday. The stock price decline reflects investor concerns over gross margin contraction.
Illumina’s Segmental Details
Illumina generates revenues from two segments – Product, and Services and other.
Product revenues totaled $990 million, up 5.4% year over year. Meanwhile, Services and other revenues amounted to $169 million, up 2.4% year over year.
ILMN’s Margins
The adjusted gross margin (including amortization of acquired intangible assets) was 65.5%, down 45 basis points (bps) year over year due to a 6.4% rise in the cost of revenues.
Research and development expenses decreased 6.6% year over year to $239 million. SG&A expenses totaled $310 million, down 11.1% from the year-ago level. Adjusted operating margin expanded 64 bps to 63.7%.
Illumina’s Financial Update
Illumina exited the fourth quarter of 2025 with cash and cash equivalents of $1.42 billion compared with $1.13 billion at the end of the fourth quarter of 2024.
Cumulative net cash provided by operating activities totaled $1.08 billion compared with $837 million a year ago.
Illumina’s 2026 Guidance
For 2026, the company expects total revenues to be in the range of $4.50-$4.60 billion, representing growth of 4-6% on a reported basis. The Zacks Consensus Estimate for 2026 revenues is currently pinned at $4.54 billion.
Non-GAAP diluted EPS is projected to be in the range of $5.05-$5.20 in 2026. The Zacks Consensus Estimate for full-year EPS is currently pegged at $5.14.
Our Take on ILMN
Illumina exited the fourth quarter of 2025 with better-than-expected results, wherein both earnings and revenues beat estimates. The company delivered a strong 2025 performance, marking a return to growth through disciplined execution.
Notable developments in the quarter include the acquisition of SomaLogic and the introduction of the Billion Cell Atlas, the first data product of the BioInsight business, to support AI-enabled drug discovery.
On the flipside, the contraction of gross margin does not bode well.
ILMN’s Zacks Rank & Key Picks
Illumina currently carries a Zacks Rank #3 (Hold).
Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $2.53, which surpassed the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.7% growth. The company beat on earnings in each of the trailing four quarters, the average surprise being 13.24%.
Envista, sporting a Zacks Rank #1 at present, posted a fourth-quarter 2025 adjusted EPS of 38 cents, exceeding the Zacks Consensus Estimate by 18.23%. Revenues of $750.6 million topped the Zacks Consensus Estimate by 411.16%.
NVST has an earnings yield of 4.7% compared with the industry’s 2.5% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.4%.
Align Technology, carrying a Zacks Rank #2 (Buy) at present, posted a fourth-quarter 2025 adjusted EPS of $3.29, which exceeded the Zacks Consensus Estimate by 10.1%. Revenues of $1.05 billion outperformed the Zacks Consensus Estimate by 5.3%.
ALGN has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.5% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.16%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips
Key Takeaways
Illumina Inc. (ILMN - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.35, which topped the Zacks Consensus Estimate by 7.4%. The figure was up 42.1% on a year-over-year basis.
Including one-time items, the company’s GAAP EPS was $2.16 compared with 73 cents a year ago.
Full-year adjusted EPS was $4.84, up 16.3% year over year.
Illumina’s Revenues
Fourth-quarter revenues amounted to $1.16 billion, up 5.4% year over year and up 4% on a constant-currency basis. The top line marginally beat the Zacks Consensus Estimate by 0.3%.
Full-year revenues amounted to $4.34 billion, up 0.2% year over year and flat on a constant-currency basis.
Following the earnings announcement, Illumina shares declined 10.4% last Friday. The stock price decline reflects investor concerns over gross margin contraction.
Illumina’s Segmental Details
Illumina generates revenues from two segments – Product, and Services and other.
Product revenues totaled $990 million, up 5.4% year over year. Meanwhile, Services and other revenues amounted to $169 million, up 2.4% year over year.
ILMN’s Margins
The adjusted gross margin (including amortization of acquired intangible assets) was 65.5%, down 45 basis points (bps) year over year due to a 6.4% rise in the cost of revenues.
Research and development expenses decreased 6.6% year over year to $239 million. SG&A expenses totaled $310 million, down 11.1% from the year-ago level. Adjusted operating margin expanded 64 bps to 63.7%.
Illumina’s Financial Update
Illumina exited the fourth quarter of 2025 with cash and cash equivalents of $1.42 billion compared with $1.13 billion at the end of the fourth quarter of 2024.
Cumulative net cash provided by operating activities totaled $1.08 billion compared with $837 million a year ago.
Illumina’s 2026 Guidance
For 2026, the company expects total revenues to be in the range of $4.50-$4.60 billion, representing growth of 4-6% on a reported basis. The Zacks Consensus Estimate for 2026 revenues is currently pinned at $4.54 billion.
Illumina, Inc. Price, Consensus and EPS Surprise
Illumina, Inc. price-consensus-eps-surprise-chart | Illumina, Inc. Quote
Non-GAAP diluted EPS is projected to be in the range of $5.05-$5.20 in 2026. The Zacks Consensus Estimate for full-year EPS is currently pegged at $5.14.
Our Take on ILMN
Illumina exited the fourth quarter of 2025 with better-than-expected results, wherein both earnings and revenues beat estimates. The company delivered a strong 2025 performance, marking a return to growth through disciplined execution.
Notable developments in the quarter include the acquisition of SomaLogic and the introduction of the Billion Cell Atlas, the first data product of the BioInsight business, to support AI-enabled drug discovery.
On the flipside, the contraction of gross margin does not bode well.
ILMN’s Zacks Rank & Key Picks
Illumina currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Envista (NVST - Free Report) and Align Technology (ALGN - Free Report) .
Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $2.53, which surpassed the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.7% growth. The company beat on earnings in each of the trailing four quarters, the average surprise being 13.24%.
Envista, sporting a Zacks Rank #1 at present, posted a fourth-quarter 2025 adjusted EPS of 38 cents, exceeding the Zacks Consensus Estimate by 18.23%. Revenues of $750.6 million topped the Zacks Consensus Estimate by 411.16%.
NVST has an earnings yield of 4.7% compared with the industry’s 2.5% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.4%.
Align Technology, carrying a Zacks Rank #2 (Buy) at present, posted a fourth-quarter 2025 adjusted EPS of $3.29, which exceeded the Zacks Consensus Estimate by 10.1%. Revenues of $1.05 billion outperformed the Zacks Consensus Estimate by 5.3%.
ALGN has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.5% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.16%.